NPM1 and chronic myelomonocytic leukemia: The FLT3 ITD (internal tandem duplication) is found in ~30% of patients with cytogenetically normal AML and predicts poor outcomes.80FLT3 mutations (ITD and tyrosine kinase domain mutations) are seen in <5% of patients with MDS and CMML and, unlike in AML, do not impact OS or LFS.7, 81 Mutations involving NPM1 (nucleophosphomin—chromosome 5q35.1) and c-Kit (chromosome 4q12) are very uncommon in CMML.7